Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice
about
Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient miceBorrelia burgdorferi binding of host complement regulator factor H is not required for efficient mammalian infectionAlternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous NephropathyDiacylglycerol Kinase-ε: Properties and Biological RolesPrimary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.Complement in glomerular injury.Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.Complement regulation in renal disease modelsMolecules Great and Small: The Complement System.Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.Review: Complement and its regulatory proteins in kidney diseases.Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies.Anaphylatoxin C5a contributes to the pathogenesis of cisplatin-induced nephrotoxicity.Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.New insights into disease-specific absence of complement factor H related protein C in mouse models of spontaneous autoimmune diseasesThe complement cascade as a mediator of tissue growth and regeneration.Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.Complement factor H deficiency accelerates development of lupus nephritis.Dense deposit disease.Clinical features and outcomes of 98 children and adults with dense deposit disease.Treatment options for C3 glomerulopathyCompstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathyIgM exacerbates glomerular disease progression in complement-induced glomerulopathyEculizumab in Pediatric Dense Deposit Disease.Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targetsComplement Dysregulation and Disease: Insights from Contemporary Genetics.The C5a receptor has a key role in immune complex glomerulonephritis in complement factor H-deficient miceLoss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency.New therapeutic targets in atrophic age-related macular degeneration.New approaches to the treatment of dense deposit disease.Membrane protein Crry maintains homeostasis of the complement system.Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release.Genetic loci modulating amyloid-beta levels in a mouse model of Alzheimer's disease.Dense deposit disease and C3 glomerulopathyNovel targets for immunotherapy in glomerulonephritis.Anticomplement therapy.
P2860
Q24651118-39A9C9F6-9B51-4AB8-A2EE-00304AF50024Q24684907-F3CCFFDD-6276-4008-B7D3-06087429A20EQ26747416-C2C7A7FD-2D60-4864-9B5A-95BD81AB7B21Q28072499-31B6D123-65F7-418E-BC3C-F2216EED7645Q33372850-7565CD07-B849-414C-A2BD-BE5E6C319764Q33376840-28D9C401-1DC5-4A11-8E81-C5B8CA466493Q33377727-3E8BDBD7-379B-49C4-9A03-28E630D67EEBQ33378236-B2A276C2-EE82-4A71-B8B1-E26A4E4E2457Q33403607-762D1B5E-017E-4EB7-9213-AD823D499DC3Q33403738-6BD9466A-925D-4B84-89B4-3FF9A97E5D69Q33411137-FFBA372D-33F4-413B-B05C-ECAA713E092CQ33419651-2D75078B-7EF8-4908-8814-7D1E01F3FDC7Q33425891-8A15BD92-1788-4032-9621-992174174ED4Q33437488-B4872B5C-AF2E-4FAA-976E-64639D576246Q33647738-B5F7D8CF-9289-4052-B665-3163FECCF738Q33711255-F545C1A4-933D-47A3-9420-9FF517EBEB3BQ33792047-22838CAF-D3C0-4731-A0A5-EFCA41FA9533Q34005720-CA68FCE5-CBB1-4CF9-90F9-D79519915FD7Q34146380-E049A22D-B4B3-4234-8DE5-C2CC5CF8FA31Q34154941-49E5755D-951C-40EC-B59F-9D7980F7CA15Q34162206-208826A9-A91C-4369-9441-0EC26D3F7DB5Q34534879-29E39E28-41D4-4D5A-9BBE-CC9D85DF1191Q35124165-F859D990-6BB8-41EC-AC8C-DF1E51A0D8E5Q35580577-00895E1A-9242-45F1-A2B8-E4F89DCBB8E5Q35624672-FBBC1A5D-A95E-48E0-8FCC-DE2E0B2CCD43Q35877192-8DCD88FA-04F9-4147-9E5B-E4ECA5E3E4DFQ36016859-16ED00D8-6AE3-4ACC-A94F-4BDB87C925EAQ36123605-49027F7C-0294-454A-BF48-5BFC1E5CD11CQ36158922-B2FB377D-2510-4104-B171-20A7DD7DD294Q36221928-531EAA80-6B6B-4CBF-A91B-4812BBBCBE76Q36320011-D1C7A918-701C-4731-A1F9-58BB12B9A168Q36509318-5451F0E8-2418-4006-9523-001E74183CCFQ36804427-69CB1E95-7F72-46F4-B493-C986EF1E07C2Q36860946-CE306409-A3BE-438D-8468-A06985107CB5Q36967101-C583081A-ED6D-4213-9B56-6D23D8209DF3Q37031990-28089D82-66B7-4E5C-850F-102C3160BAA9Q37100751-8C9F1FA6-987B-4696-9797-97162DFC33DAQ37286653-76295BA8-68EB-4852-AD9D-0452CE78656CQ37290692-E12AA6D3-5C35-4882-8F9E-D35A9F5A9C70Q37307880-A56A024D-402A-48A5-9B46-65616CBD0AD9
P2860
Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Prevention of C5 activation am ...... tis in factor H-deficient mice
@ast
Prevention of C5 activation am ...... tis in factor H-deficient mice
@en
Prevention of C5 activation am ...... tis in factor H-deficient mice
@nl
type
label
Prevention of C5 activation am ...... tis in factor H-deficient mice
@ast
Prevention of C5 activation am ...... tis in factor H-deficient mice
@en
Prevention of C5 activation am ...... tis in factor H-deficient mice
@nl
prefLabel
Prevention of C5 activation am ...... tis in factor H-deficient mice
@ast
Prevention of C5 activation am ...... tis in factor H-deficient mice
@en
Prevention of C5 activation am ...... tis in factor H-deficient mice
@nl
P2093
P2860
P356
P1476
Prevention of C5 activation am ...... tis in factor H-deficient mice
@en
P2093
P2860
P304
P356
10.1073/PNAS.0601094103
P407
P577
2006-06-12T00:00:00Z